Pricing Log in Create free account
Sunday 18 October 2026 Export AGEN’s income statement to Excel — free account

Agenus Inc.

AGEN Healthcare Biotechnology

Agenus Inc.’s revenue for fiscal 2025 (year ended December 2025) was $114.2 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 34.4%, EPS grew 98.6%, free cash flow fell 55.3% and total debt fell 11.2%, each against the same quarter a year earlier.

6.04 0.64 −9.58%
Market cap
$301.7M
P/E
2.3×
Fwd P/E
4.1×
Dividend yield
—
F-score
4/9
Altman Z
−14.16
Beneish M
12.57
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Agenus Inc. (AGEN) Business Profile

Updated before January 2025

Company Overview

Agenus Inc. (NASDAQ: AGEN) is a biotechnology company dedicated to the discovery and development of innovative immunotherapies for cancer and infectious diseases. Founded in 1994 and headquartered in Lexington, Massachusetts, Agenus has been at the forefront of immuno-oncology research for nearly three decades. The company was established by Garo H. Armen, Ph.D., who currently serves as the Chairman and Chief Executive Officer. Under his leadership, Agenus has grown into a prominent player in the biotechnology sector, leveraging cutting-edge science to develop therapies that harness the power of the immune system.

Agenus operates with a mission to deliver transformative therapies to patients in need. The company has built a robust pipeline of immune-modulating antibodies, vaccines, and adjuvants, supported by a team of experienced scientists, researchers, and industry professionals. Agenus has also established strategic partnerships with leading pharmaceutical companies to accelerate the development and commercialization of its products.

Core Business Segments

Agenus focuses on three primary business segments: immune checkpoint antibodies, cancer vaccines, and adjuvants. Each segment plays a critical role in the company’s mission to advance immunotherapy.

Immune Checkpoint Antibodies

Agenus develops a range of immune checkpoint antibodies designed to enhance the immune system’s ability to detect and destroy cancer cells. Key products in this category include:

  • Balstilimab (anti-PD-1): A monoclonal antibody targeting the PD-1 pathway, which is critical in suppressing the immune response in cancer patients. Balstilimab is being evaluated for its efficacy in treating various cancers, including cervical cancer.
  • Zalifrelimab (anti-CTLA-4): Another monoclonal antibody that targets the CTLA-4 pathway, enhancing T-cell activation and proliferation to combat tumors.
  • AGEN2373 (anti-CD137): A novel antibody designed to stimulate immune cells and improve anti-tumor responses.

Cancer Vaccines

Agenus is pioneering the development of personalized cancer vaccines that are tailored to individual patients. These vaccines are designed to stimulate the immune system to recognize and attack cancer cells. Key initiatives include:

  • AutoSynVax™: A neoantigen vaccine platform that uses patient-specific tumor antigens to create a personalized therapeutic vaccine.
  • PhosphoSynVax™: A vaccine platform targeting phosphopeptides, which are unique to cancer cells.

Adjuvants

Agenus has a long history of developing adjuvants, which are substances that enhance the efficacy of vaccines. The company’s proprietary adjuvants include:

  • QS-21 Stimulon®: A saponin-based adjuvant that has been widely used in vaccines for infectious diseases and cancer. QS-21 is a key component of several approved vaccines, including the Shingrix® vaccine for shingles.

Business Model

Agenus operates on a hybrid business model that combines in-house research and development with strategic partnerships. The company generates revenue through multiple streams, including:

  1. Product Sales: Agenus earns revenue from the sale of its proprietary adjuvants and other immunotherapy products.
  2. Collaborations and Licensing: The company has established partnerships with major pharmaceutical companies, such as Gilead Sciences and Merck, to co-develop and commercialize its therapies. These collaborations provide upfront payments, milestone payments, and royalties.
  3. Grants and Funding: Agenus receives funding from government agencies and non-profit organizations to support its research initiatives.

This diversified approach allows Agenus to mitigate risks and accelerate the development of its pipeline.

Strategic Direction

Agenus is committed to advancing its pipeline of immunotherapies and expanding its presence in the global oncology market. Key strategic priorities include:

  • Pipeline Expansion: Agenus aims to advance its clinical-stage programs, including balstilimab and zalifrelimab, while exploring new targets for immunotherapy.
  • Global Partnerships: The company plans to strengthen its collaborations with pharmaceutical partners to accelerate the commercialization of its products.
  • Sustainability Goals: Agenus is focused on developing cost-effective therapies that are accessible to patients worldwide. The company is also exploring environmentally sustainable practices in its operations.
  • New Product Categories: Agenus is investing in next-generation technologies, such as bispecific antibodies and cell therapies, to diversify its product portfolio.

Competitive Landscape

Agenus operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Bristol-Myers Squibb: A leader in immuno-oncology with products like Opdivo® and Yervoy®.
  • Merck & Co.: Known for its blockbuster PD-1 inhibitor, Keytruda®.
  • Roche: A major player in cancer immunotherapy with products like Tecentriq®.
  • Innovative Biotech Startups: Companies like Moderna and BioNTech are also exploring immunotherapy solutions.

Despite the competition, Agenus differentiates itself through its innovative pipeline and strategic partnerships.

Risk Factors

Agenus faces several risks that could impact its business operations and financial performance:

  • Regulatory Challenges: The approval process for new therapies is lengthy and uncertain, posing a risk to product commercialization.
  • Market Dependence: Agenus relies heavily on the success of its lead candidates, such as balstilimab, which increases its exposure to market fluctuations.
  • Supply Chain Disruptions: The company depends on third-party manufacturers for the production of its therapies, making it vulnerable to supply chain issues.
  • Competition: Intense competition in the biotechnology sector could limit Agenus’s market share and pricing power.

Recent Developments

Agenus has made significant progress in advancing its pipeline and corporate strategy. Recent highlights include:

  • Clinical Trials: The company has reported positive data from clinical trials of balstilimab and zalifrelimab, demonstrating their potential as effective cancer therapies.
  • Partnerships: Agenus has expanded its collaboration with Gilead Sciences to include additional targets for immunotherapy.
  • Innovations: The company is exploring the use of artificial intelligence and machine learning to accelerate drug discovery and development.
  • Global Events: The COVID-19 pandemic has underscored the importance of immunotherapy, driving increased interest in Agenus’s research.

Investment Considerations

Investors considering Agenus should weigh the following strengths and risks:

Strengths

  • Innovative Pipeline: Agenus has a diverse portfolio of immunotherapies with significant market potential.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies provide financial stability and access to resources.
  • Experienced Leadership: The company is led by a seasoned management team with a proven track record in biotechnology.

Risks

  • Financial Performance: Agenus is not yet profitable and relies on external funding to support its operations.
  • Regulatory Uncertainty: The approval process for new therapies is unpredictable and could delay commercialization.
  • Market Competition: The biotechnology sector is highly competitive, with numerous players vying for market share.

Conclusion

Agenus Inc. is a pioneering biotechnology company with a strong focus on immunotherapy. With a robust pipeline, strategic partnerships, and a commitment to innovation, Agenus is well-positioned to capitalize on the growing demand for cancer and infectious disease therapies. While the company faces challenges, such as regulatory hurdles and market competition, its long-term growth prospects remain promising. Agenus represents a compelling opportunity for investors seeking exposure to the biotechnology sector.